Amygdalin inhibits genes related to cell cycle in SNU-C4 human colon cancer cells

  • World J Gastroenterol. 2005 Sep 7;11(33):5156-61. doi: 10.3748/wjg.v11.i33.5156.
Hae-Jeong Park  1 ,  Seo-Hyun Yoon ,  Long-Shan Han ,  Long-Tai Zheng ,  Kyung-Hee Jung ,  Yoon-Kyung Uhm ,  Je-Hyun Lee ,  Ji-Seon Jeong ,  Woo-Sang Joo ,  Sung-Vin Yim ,  Joo-Ho Chung ,  Seon-Pyo Hong
Affiliations
  • 1. Department of Pharmacology, Kohwang Medical Research Institute, College of Pharmacy, Kyung Hee University, Seoul 130-701, South Korea.
PMID: 16127745 DOI: 10.3748/wjg.v11.i33.5156
Abstract

Aim: The genes were divided into seven categories according to biological function; apoptosis-related, immune response-related, signal transduction-related, cell cycle-related, cell growth-related, stress response-related and transcription-related genes.

Methods: We compared the gene expression profiles of SNU-C4 cells between amygdalin-treated (5 mg/mL, 24 h) and non-treated groups using cDNA microarray analysis. We selected genes downregulated in cDNA microarray and investigated mRNA levels of the genes by RT-PCR.

Results: Microarray showed that amygdalin downregulated especially genes belonging to cell cycle category: exonuclease 1 (EXO1), ATP-binding cassette, sub-family F, member 2 (ABCF2), MRE11 meiotic recombination 11 homolog A (MRE11A), Topoisomerase (DNA) I (TOP1), and FK506 binding protein 12-rapamycin-associated protein 1 (FRAP1). RT-PCR analysis revealed that mRNA levels of these genes were also decreased by amygdalin treatment in SNU-C4 human colon Cancer cells.

Conclusion: These results suggest that amygdalin have an Anticancer effect via downregulation of cell cycle-related genes in SNU-C4 human colon Cancer cells, and might be used for therapeutic Anticancer drug.

Products